Dual-Mechanism Drop Wins FDA Approval - Takeaways - MDSpire

Dual-Mechanism Drop Wins FDA Approval

FDA approves Tenpoint Therapeutics’ YUVEZZI eye drop for presbyopia

February 2, 2026
2 min

The Ophthalmologist

Share

1

YUVEZZI™ is the first FDA-approved dual-agent eye drop for treating presbyopia in adults.
2

The formulation combines carbachol and brimonidine tartrate to improve near visual acuity while preserving distance vision.
3

FDA approval was based on two Phase 3 trials, BRIO I and BRIO II, involving over 800 patients.
4

YUVEZZI demonstrated significant improvements in near vision without serious adverse events during extensive safety studies.
5

The product is expected to be commercially available in the US by the second quarter of 2026.

Original Source(s)

The Ophthalmologist

Dual-Mechanism Drop Wins FDA Approval

February 2, 2026

Related Content

Contact Lens Spectrum

Multifocal Mythbusting

Concerns about chair time, adaptation issues, and inconsistent vision are rooted in outdated perceptions shaped by earlier generations of lenses and overshadow the many benefits that multifocal contact lenses can offer patients who have presbyopia.

by Michael Shaheen, OD
May 1, 2026
4 min

Optometric Management

Presbyopia Solutions for Patients With Retinal Disease

When prescribing spectacle lenses, one of the most impactful things we can do is ask: “What are your visual goals?” or more simply, “What are you struggling to see clearly?”